Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125324331 | 12532433 | 1 | I | 20150701 | 20160706 | 20160706 | PER | US-PURDUE-USA-2015-0124656 | PURDUE | 0.00 | F | Y | 0.00000 | 20160706 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125324331 | 12532433 | 1 | PS | BUTRANS | BUPRENORPHINE | 1 | Transdermal | 5 MCG/HR, WEEKLY | U | U | UNKNOWN | 21306 | TRANSDERMAL PATCH | ||||||
125324331 | 12532433 | 2 | SS | SUBOXONE | BUPRENORPHINE HYDROCHLORIDENALOXONE HYDROCHLORIDE | 1 | Oral | 8 MG, UNK | U | UNKNOWN | 0 | 8 | MG | ||||||
125324331 | 12532433 | 3 | SS | SUBOXONE | BUPRENORPHINE HYDROCHLORIDENALOXONE HYDROCHLORIDE | 1 | Oral | UNK | U | UNKNOWN | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125324331 | 12532433 | 1 | Product used for unknown indication |
125324331 | 12532433 | 2 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125324331 | 12532433 | Drug withdrawal syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125324331 | 12532433 | 1 | 201506 | 0 | ||
125324331 | 12532433 | 2 | 201506 | 0 | ||
125324331 | 12532433 | 3 | 2009 | 0 |